Literature DB >> 2039380

Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988.

J F Annegers1, S Appel, J R Lee, P Perkins.   

Abstract

The incidence of amyotrophic lateral sclerosis was determined in Harris County, Texas, for the period 1985 through 1988. Amyotrophic lateral sclerosis cases were ascertained from four sources: area neurologists, hospitals, death certificates, and the Muscular Dystrophy Association. The age-adjusted incidences of 1.27 per 100,000 person-years in males and 1.03 per 100,000 person-years in females were lower than recent rates in the northern US, Canadian, and northern European studies but higher than rates in southern European studies. Comparisons with other recent incidence studies show less uniformity in occurrence of amyotrophic lateral sclerosis, in both the overall rates and in the age- and sex-specific patterns, than was suggested by mortality studies. The incidence of amyotrophic lateral sclerosis among blacks and whites was similar. Hispanic males had incidences similar to white males, although a deficit of female Hispanic cases was found in Harris County. The prevalence of amyotrophic lateral sclerosis peaked in the 65- to 74-year age group at 33 per 100,000 population among males and 19 per 100,000 population for females.

Entities:  

Mesh:

Year:  1991        PMID: 2039380     DOI: 10.1001/archneur.1991.00530180041015

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  25 in total

Review 1.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

Review 2.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

3.  Amyotrophic lateral sclerosis: from pathological mechanisms to patient care.

Authors:  G Scarlato
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

4.  Changing mortality for motor neuron disease in France (1968-2007): an age-period-cohort analysis.

Authors:  Paul H Gordon; Fanny Artaud; Albertine Aouba; Françoise Laurent; Vincent Meininger; Alexis Elbaz
Journal:  Eur J Epidemiol       Date:  2011-06-15       Impact factor: 8.082

5.  Age-specific ALS incidence: a dose-response meta-analysis.

Authors:  Benoît Marin; Andrea Fontana; Simona Arcuti; Massimilano Copetti; Farid Boumédiene; Philippe Couratier; Ettore Beghi; Pierre Marie Preux; Giancarlo Logroscino
Journal:  Eur J Epidemiol       Date:  2018-04-23       Impact factor: 8.082

Review 6.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Brain plasticity in the motor network is correlated with disease progression in amyotrophic lateral sclerosis.

Authors:  Aurélia Poujois; Fabien C Schneider; Isabelle Faillenot; Jean-Philippe Camdessanché; Nadia Vandenberghe; Catherine Thomas-Antérion; Jean-Christophe Antoine
Journal:  Hum Brain Mapp       Date:  2012-03-28       Impact factor: 5.038

Review 8.  Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.

Authors:  A Chiò; G Logroscino; B J Traynor; J Collins; J C Simeone; L A Goldstein; L A White
Journal:  Neuroepidemiology       Date:  2013-07-11       Impact factor: 3.282

9.  Trends in motor neuron disease: association with latitude and air lead levels in Spain.

Authors:  Ana Santurtún; Alejandro Villar; Manuel Delgado-Alvarado; Javier Riancho
Journal:  Neurol Sci       Date:  2016-04-20       Impact factor: 3.307

Review 10.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.